Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Hisse Senetlerindeki Sıralama #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Hisse Fiyatı
$0.5225
Son senkronizasyon: 2026-08-14
Piyasa Değeri
$4.32M
Değişim (1 gün)
-1.60%
Değişim (1 yıl)
-63.72%
Ülke
IL
Ticaret Galmed Pharmaceuticals Ltd. (GLMD)

Kategori

Galmed Pharmaceuticals Ltd. (GLMD) için EPS
2026 itibariyle EPS TTM: 0
Galmed Pharmaceuticals Ltd. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
Galmed Pharmaceuticals Ltd. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS